The U.S. Case is more important because of the economic implications. It (the U.K. Ruling) is a nice psychological boost but you can't extrapolate the U.S. Ruling from this because of the different legal standards.
Catherine Arnold
We think the downside risk here is modest. Merck has fundamental challenges ahead based on its base business. We really concluded the stock is trading incorporating these items.
business challenges risk
legal nice psychological standards important
This is half the savings that Pfizer achieved with its recently announced program.
savings
After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings per share growth in 2007-2010.
growth share teens return
We just can't get there. Maybe they see something we don't see.
Lilly's current valuation still provides an attractive entry point. The stock trades at a modest 8% to 10% premium to its peers against 2006 and 2007 earnings and at a discount against our 2008 to 2010 forecast.
attractive
Schering-Plough shares are most likely to be impacted by first quarter 2006 results.
results
You must log in to post a comment.
There are no comments yet.